This inventor holds 4 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignees: Boehringer Mannheim Gmbh, Heinrich-Pette-Institut, Heinrich-Pette-Institute. Active years: 1999-2014.
Company Filing History:
1 out of 1,164 
1 out of 3 
1 out of 2 
Years Active: 1999-2014
Title: Christopher Baum: Innovator in Retroviral Vector Technology
Introduction
Christopher Baum is a prominent inventor based in Hamburg, Germany. He has made significant contributions to the field of gene transfer technology, particularly through his innovative work on retroviral vectors. With a total of 4 patents, Baum's inventions have the potential to advance therapeutic applications in medicine.
Latest Patents
One of Baum's latest patents is the ASLV vector system. This invention provides a viral self-inactivating (SIN) vector based on the avian sarcoma leukosis virus (ASLV). It includes a split-packaging system that comprises a first helper plasmid for the expression of the viral fusion protein gag-pol and a second helper plasmid for the expression of the retroviral envelope protein (env). The system generates non-replicating viral particles containing RNA with a SIN LTR at the 3' terminus, which can include a therapeutically effective transgene. Additionally, Baum has developed retroviral vectors with foreign-sequence insertion between the retroviral primer binding site and the retroviral splice donor. This modification improves gene expression efficiency and enhances the reliability of the vectors during use.
Career Highlights
Throughout his career, Christopher Baum has worked with esteemed institutions such as the Heinrich Pette Institute. His research has focused on advancing the understanding and application of retroviral vectors in gene therapy.
Collaborations
Baum has collaborated with notable colleagues, including Wolfram Ostertag and Daniel Schaumann. Their combined expertise has contributed to the success of various projects in the field of gene transfer technology.
Conclusion
Christopher Baum's innovative work in retroviral vector technology has positioned him as a key figure in the advancement of gene therapy. His patents reflect a commitment to improving therapeutic outcomes through scientific innovation.